Functional subtypes of renal alpha1-adrenoceptor in diabetic and non-diabetic 2K1C Goldblatt renovascular hypertension.
A Armenia, Munavvar Abdul Sattar, Nor Azizan Abdullah, Md Abdul Hye Khan, Edward James Johns
Index: Acta Pharmacol. Sin. 29(5) , 564-72, (2008)
Full Text: HTML
Abstract
This study investigates the subtypes of the alpha1-adrenoceptor mediating the adrenergically-induced renal vasoconstrictor responses in streptozotocin-induced diabetic and non-diabetic 2-kidney one clip (2K1C) Goldblatt hypertensive rats.The renal blood flow responses to renal nerve stimulation, noradrenaline, phenylephrine, and methoxamine were measured in the absence and presence of nitrendipine, 5-methylurapidil, chloroethylclonidine and BMY 7378.The renal vasoconstrictor responses were markedly attenuated by nitrendipine and 5- methylurapidil in the diabetic rats (all P< 0.05). In the non-diabetic rats, these responses were markedly attenuated by nitrendipine, 5-methylurapidil, and BMY 7378 (all P< 0.05). In both experimental groups, chloroethylclonidine markedly accentuated the renal vasoconstrictions caused by all the adrenergic stimuli (all P< 0.05).These observations indicate that alpha 1A-adrenoceptor subtypes play a major role in mediating adrenergically-induced renal vasoconstriction in the diabetic 2K1C Goldblatt hypertensive rats. In the non-diabetic 2K1C Goldblatt hypertensive rats, contributions of alpha 1A and alpha 1D-adrenoceptor subtypes were proposed. Apart from post-synaptic alpha 1-adrenoceptors, both in the diabetic and non-diabetic 2K1C Goldblatt hypertensive rats, the potential involvement of presynaptic alpha 1- adrenoceptors is also suggested.
Related Compounds
Related Articles:
2011-07-01
[Anal. Bioanal. Chem 400(10) , 3625-33, (2011)]
2009-01-01
[Auton. Autacoid Pharmacol. 29(1-2) , 25-31, (2009)]
Alpha-1A adrenergic receptor activation increases inhibitory tone in CA1 hippocampus.
2009-04-01
[Epilepsy Res. 84(2-3) , 97-109, (2009)]
2006-02-01
[Arch. Physiol. Biochem. 112(1) , 23-30, (2006)]
2007-08-13
[Eur. J. Pharmacol. 569(1-2) , 110-8, (2007)]